2.7.7.12	1,10-phenanthroline	inactivation of the enzyme by chelation of Zn2+ and Fe2+ ions, UDP-glucose protects, but alpha-D-glucose 1-phosphate does not	62	
2.7.7.12	1,10-phenanthroline	mutant E182A	62	
2.7.7.12	2,2'-bipyridyl	inactivation of the enzyme by chelation of Zn2+ and Fe2+ ions	1706	
2.7.7.12	2-fluoro-galactose-1-phosphate	competitively inhibit recombinant enzyme	256871	
2.7.7.12	8-hydroxyquinoline	inactivation of the enzyme by chelation of Zn2+ and Fe2+ ions	321	
2.7.7.12	8-Hydroxyquinoline sulfonate	inactivation of the enzyme by chelation of Zn2+ and Fe2+ ions	45992	
2.7.7.12	ADP	erythrocytes	13	
2.7.7.12	ADP	-	13	
2.7.7.12	ADP-glucose	-	598	
2.7.7.12	alpha-D-galactose 1-phosphate	product/substrate inhibition	493	
2.7.7.12	alpha-D-galactose 1-phosphate	-	493	
2.7.7.12	alpha-D-galactose 1-phosphate	substrate inhibition at concentrations above 1.5 mM	493	
2.7.7.12	alpha-D-galactose 1-phosphate	competitive substrate inhibition in the forward reaction	493	
2.7.7.12	alpha-D-glucose 1-phosphate	erythrocytes	107	
2.7.7.12	alpha-D-glucose 1-phosphate	product/substrate inhibition	107	
2.7.7.12	alpha-D-glucose 1-phosphate	-	107	
2.7.7.12	ATP	erythrocytes	4	
2.7.7.12	ATP	-	4	
2.7.7.12	Ca2+	-	15	
2.7.7.12	CDP-glucose	-	2439	
2.7.7.12	Cl-	-	141	
2.7.7.12	Cu2+	-	19	
2.7.7.12	cycloheximide	i.e. 3-[2-(3,5-dimethyl-2-oxocyclohexyl)-2-hydroxyethyl]glutarimide; inhibition of de novo enzyme synthesis; mutant N314D is more sensitive than the wild-type	1715	
2.7.7.12	D-galactose	wild-type and mutants, inverse relationship between enzyme activity and galactose sensitivity	71	
2.7.7.12	D-galactose	galactosemia, disease caused by genetic disorder, is characterized by a galactose sensitivity	71	
2.7.7.12	D-glucose 6-phosphate	erythrocytes	105	
2.7.7.12	diethyl dicarbonate	inactivates the enzyme, reversable by hydroxylamine	463	
2.7.7.12	diethyldicarbonate	erythrocytes	310	
2.7.7.12	DTNB	binds to SH-group in the active center	554	
2.7.7.12	GDP-glucose	-	1105	
2.7.7.12	HgCl2	94% inhibition at 0.2 mM	110	
2.7.7.12	iodoacetate	no inhibition	93	
2.7.7.12	iodoacetate	erythrocytes	93	
2.7.7.12	Mg2+	-	6	
2.7.7.12	Mn2+	-	11	
2.7.7.12	additional information	no inhibition by NaF	2	
2.7.7.12	additional information	product inhibition study, wild-type and mutants H166G and H166A	2	
2.7.7.12	additional information	no inhibition by NADH, NAD+, sodium diphosphate	2	
2.7.7.12	NEM	no inhibition	89	
2.7.7.12	NEM	complete inhibition at 0.05 mM	89	
2.7.7.12	p-hydroxymercuribenzoate	complete inhibition at 0.001 mM	98	
2.7.7.12	PCMB	42% inhibition at 0.2 mM	78	
2.7.7.12	PCMB	erythrocytes	78	
2.7.7.12	TDP-glucose	-	1766	
2.7.7.12	UDP	-	26	
2.7.7.12	UDP-alpha-D-glucose	-	364	
2.7.7.12	UDP-galactose	product/substrate inhibition	129	
2.7.7.12	UDP-galactose	the product of the forward reaction is a competitive inhibitor with respect to UDP-glucose and a mixed inhibitor with respect to galactose 1-phosphate	129	
2.7.7.12	UDP-glucose	product inhibition	64	
2.7.7.12	UDP-glucose	product/substrate inhibition	64	
2.7.7.12	UDP-glucose	-	64	
2.7.7.12	UDP-glucose	substrate inhibition at concentrations above 0.5 mM	64	
2.7.7.12	UDP-glucose	at high concentrations, wild-type and mutants F171L and F171S, not F171Y	64	
2.7.7.12	UDP-glucuronic acid	-	1225	
2.7.7.12	UDP-mannose	-	2988	
2.7.7.12	UDP-xylose	-	1013	
2.7.7.12	UMP	-	133	
2.7.7.12	Uracil	-	334	
2.7.7.12	uridine	-	261	
2.7.7.12	UTP	-	65